Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 2Head & Neck 1Genitourinary 1Breast 1

Conditions

Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 23Gemcitabine 14Carboplatin 10Nivolumab 9Cyclophosphamide 9olaparib 8Specimen Handling 8Paclitaxel 8Trastuzumab 7Magnetic Resonance Spectroscopy 6fludarabine 5Standard of Care 5Irinotecan 5Ipilimumab 5Docetaxel 5Cisplatin 5Capecitabine 5Biopsy 5sargramostim 4pertuzumab 4palbociclib 4enzalutamide 4durvalumab 4atezolizumab 4aldesleukin 4Taxes 4Oxaliplatin 4Fluorouracil 4Erlotinib Hydrochloride 4Early Intervention, Educational 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × budigalimab × Genitourinary × Clear all
NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Trishula Therapeutics, Inc.

Phase 1 Completed
185 enrolled 28 charts
GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡